PhD Research Intern - Measurement and Evaluation

Abridge announced a pre-bill review capability for clinical documentation integrity (CDI), coding, and revenue cycle teams. The feature reviews inpatient claims before submission, comparing final coded diagnoses and diagnosis-related groups (DRG) against clinical documentation. The platform identifies discrepancies and provides supporting evidence, allowing teams to resolve issues before claims become denials. Abridge does not alter documentation, codes, or claim status—CDI teams retain control over holding, correcting, or releasing claims. The capability builds on Abridge's existing clinician intelligence platform, which captures records during clinical interactions. By extending this platform into pre-bill review, Abridge enables comparison between clinical records and claim diagnoses before submission. This approach aims to ensure coded records accurately reflect the documented complexity of care, addressing the gap between care delivery and reimbursement.

Top Pharma news: July 2026. Posts You Might Like What were the top pharma news stories as of July 2026? July's pharmaceutical landscape was shaped by continued U.S. drug pricing reform, a breakthrough in cancer treatment innovation, and expanding investment in artificial intelligence across healthcare. The Trump administration moved to strengthen Medicare drug pricing regulations, China approved the world's first CAR-T therapy for solid tumors, and leading healthcare organizations accelerated AI adoption to improve drug development, clinical decision-making, and specialty pharmacy services. The Fullintel Hub keeps stakeholders informed as these developments unfold. June 2026 Pharma news breakdown. What does the proposed CMS rule signal about the administration's drug pricing strategy? The Trump administration proposed a comprehensive rule through the Centers for Medicare and Medicaid Services to codify federal Medicare drug price negotiations permanently. This measure closes a major regulatory loophole that previously allowed pharmaceutical companies to avoid mandated price caps simply by adding active ingredients or slightly reformulating existing single-source medications. What it means: * The proposal strengthens the long-term stability of Medicare drug price negotiations by reducing opportunities for legal or regulatory challenges. * Drug manufacturers may face increased pressure to align pricing strategies with negotiated Medicare prices, closing off traditional product-hopping workarounds. * The move reinforces drug affordability as a central healthcare policy priority while increasing scrutiny of pharmaceutical pricing practices. Social media sentiment was generally positive, with "Love" and "Wow" reactions reflecting support for closing corporate loopholes and reducing out-of-pocket prescription costs for seniors. Limited negative sentiment likely reflected skepticism over whether drugmakers might find new regulatory workarounds or reduce overall investment in drug discovery. Why is CARsgen's approval considered a milestone? China approved CARsgen Therapeutics' satricabtagene autoleucel, making it the world's first CAR-T therapy approved for treating solid tumors. The therapy targets Claudin18.2-positive gastric and gastroesophageal junction cancers, representing a major scientific breakthrough after years of limited success applying CAR-T technology beyond blood cancers. What it means: * The approval establishes proof of concept for CAR-T therapies in solid tumors, addressing one of oncology's biggest unmet challenges. * China continues strengthening its position as a global leader in advanced cell and gene therapy innovation, raising questions about when Western regulatory bodies like the U.S. FDA will follow. * The decision is expected to accelerate investment in next-generation CAR-T platforms targeting additional solid tumor indications, opening doors for broader commercial applications in hard-to-treat cancers. Social media sentiment was generally positive, with dominant "Love" and "Wow" reactions reflecting support for lower out-of-pocket drug costs and innovative medicine. The pulse: AI in healthcare. 1. Nvidia, Abridge collaborate to develop healthcare-specific AI model. Nvidia and healthcare AI company Abridge announced a collaboration to develop healthcare-specific foundation models designed to improve clinical documentation, physician workflows, and medical decision support. The partnership combines Nvidia's AI infrastructure with Abridge's expertise in clinical language models to expand generative AI adoption across healthcare systems. * Coverage Sentiment: Positive. Analysts view the partnership as another major step toward specialized AI models built specifically for healthcare applications. * Dominant Social Sentiment: "Wow" - Healthcare technology communities praised the collaboration for addressing clinician burnout while improving documentation accuracy. * News Source: Fierce Healthcare 2. Cigna invests $100M in new ai-powered specialty pharmacy program. Cigna announced a $100M investment to launch a new AI-powered specialty pharmacy program designed to improve patient support, streamline prior authorization processes, and optimize medication management for complex diseases. * Coverage Sentiment: Positive. Coverage emphasized operational efficiency and improved patient engagement through AI-enabled pharmacy services. * Dominant Social Sentiment: "Love" - Discussion focused on AI's potential to simplify specialty pharmacy experiences while reducing administrative burdens. * News Source: Reuters 3. AstraZeneca CEO says AI is reshaping drug development and helping boost the odds of success. AstraZeneca CEO Pascal Soriot stated that artificial intelligence is significantly improving the probability of success throughout the drug discovery and development process. AI is increasingly being integrated into target identification, clinical trial design, and molecule optimization to accelerate research while reducing development costs. * Coverage Sentiment: Positive. Industry observers increasingly view AI as a competitive advantage for pharmaceutical R&D. * Dominant Social Sentiment: "Wow" - Conversations centered on AI's growing role in transforming pharmaceutical innovation and improving research productivity. * News Source: CNBC Key pharmaceutical industry takeaways for July 2026. What do these developments signal for the health and life sciences industry? * Medicare drug pricing reform continues to evolve, with policymakers focusing on strengthening the regulatory framework supporting negotiated drug prices. * Cell therapy innovation has entered a new phase as CAR-T technology expands beyond blood cancers into solid tumor treatment. * AI investment is accelerating across the healthcare ecosystem, extending beyond research into clinical operations, pharmacy services, and physician workflows. * Specialized healthcare AI models are emerging as the preferred strategy for improving clinical accuracy and operational efficiency. * Global competition in pharmaceutical innovation continues to intensify, with China demonstrating increasing leadership in advanced oncology therapies. About Fullintel's pharmaceutical news Coverage. The Fullintel Hub delivers daily pharmaceutical news analysis and insights to support PR and communications teams. Its human analysts track key developments across traditional media, social platforms, and industry publications. Its award-winning methodology, including its proprietary Media Impact Score and Trust Score, helps organizations refine messaging and benchmark against competitors. About Fullintel Strategic Media Analysis. Fullintel's Strategic Media Analysis measures the true impact of PR and communications efforts for pharmaceutical and healthcare organizations. Angela Dwyer, VP of Insights, leads its pharmaceutical analysis practice. Her original trust factor research has been presented at PRSA ICON and IPR conferences, and she has been named a PRNEWS Top Women Award recipient and 2025 AMEC Award winner. Angela Dwyer. Angela is VP of Insights at Fullintel - a media intelligence company that specializes in news monitoring and analysis. She has worked in media measurement for 15 years, helping brands improve business results through data-driven, actionable insights. From public relations agencies like Lippe Taylor to media research firms like PRIME Research, she has consulted across industries, particularly healthcare and pharmaceuticals. She has presented and published several award-winning research papers about news content that drives recall, engagement, and brand trust. Her "Trust in Pharma" research outlines how biopharma brands can build and sustain trust. She contributes knowledge at the intersection of academia and practice as director of the International Public Relations Measurement Commission and as a member of the International Public Relations Research Conference Board. Her contributions have been recognized with multiple industry awards, including PRNEWS People of the Year (Data & Measurement Game Changer), PRNEWS Top Women (Industry Champions), and AMEC Rising Star for innovation in communication measurement. Learn more about Angela Dwyer's expertise, industry recognition, and thought leadership.